Cover Image

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

Saved in:

Bibliographic Details
Main Authors:	Sirin Falconi (Author), Abiodun Okimi (Author), Shaun Wesley (Author), Pooja Sethi (Author), Palika Datta (Author), Kaytlin Krutsch (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
by: Sirin Falconi, et al.
Published: (2024)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022)

Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018)

Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023)

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
by: Rui Zhang MD, PhD, et al.
Published: (2022)

Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan)
by: Ashley L. Eadie, et al.
Published: (2021)

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
by: Cuthbert JJ, et al.
Published: (2020)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
by: Shuangcui Wang, et al.
Published: (2023)

Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
by: Mohammed Habib
Published: (2018)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020)

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
by: Bartosz Sadłowski, et al.
Published: (2024)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins
by: Fukun Zhao, et al.
Published: (2024)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
by: Zakiyah N, et al.
Published: (2021)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
by: Vilela-Martin JF
Published: (2016)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)

Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan
by: Lena Holmlund, et al.
Published: (2020)

Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure
by: Sara Mucherino, et al.
Published: (2023)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
by: Wenchao Zhang, et al.
Published: (2021)

Preliminary results of investigation regarding influence of sacubitril/valsartan supramolecular complex on healthcare resource consumption
by: K. A. Serenko, et al.
Published: (2018)

Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan
by: Kamila Babkiewicz-Jahn, et al.
Published: (2024)

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
by: Qian Xiang, et al.
Published: (2022)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
by: Velia Cassano, et al.
Published: (2022)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
by: Yue Wu, et al.
Published: (2020)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
by: Helena Norberg, et al.
Published: (2019)

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
by: Yiwen Wang, et al.
Published: (2024)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
by: Elodie Charuel, et al.
Published: (2021)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
by: Tara Snyder, et al.
Published: (2019)

Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan
by: Dana Dadanbekova, et al.
Published: (2024)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
by: T. V. Ashcheulova, et al.
Published: (2019)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
by: Yake Lou, et al.
Published: (2022)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
by: Jianbin Qin, et al.
Published: (2022)

Sacubitril-valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018)

Quality of life of patients with cardiomyopathy treated with sacubitril/valsartan vs. standard therapy during or after COVID-19 in Kazakhstan
by: Dana Dadanbekova, et al.
Published: (2024)

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
by: Shih-Hsing Lo, et al.
Published: (2021)

Predicting Hospital Readmissions in Patients Receiving Novel-Dose Sacubitril/Valsartan Therapy: A Competing-Risk, Causal Mediation Analysis
by: Changchun Hou MD, et al.
Published: (2023)